BioMed Research International / 2014 / Article / Tab 3

Research Article

Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients

Table 3

Current antiretroviral therapy during coronary event and at the last follow-up visit.

Coronary event
(%)
Last follow-up visita
(%)
valueb

Without treatment ()17 (20)11 (14)0.3
PI-based regimen ()33 (41)35 (43)0.87
 PI (with an unfavorable lipid profile)22 (67)13 (37)0.028
  Indinavir/r7 (21)2 (6)0.13
  Lopinavir/r15 (45)10 (29)0.23
  Fosamprenavir/r01 (3)1
 PI (with a favorable lipid profile)11 (33)22 (63)0.028
  Saquinavir/r2 (6)00.45
  Atazanavir/r6 (18)11 (31)0.33
  Darunavir/r3 (9)11 (31)0.048
NNRTI-based regimen ()26 (32)31 (38)0.51
 Nevirapine15 (58)14 (45)0.5
 Efavirenz11 (42)17 (55)0.5
Other treatments ()6 (7)4 (5)0.74
Without treatment05 (33)1

Nucleoside reverse transcriptase inhibitor
Abacavir15 (52)14 (48)1

aMedian time (IQR) from the coronary event until the last follow-up visit (June 2011): 7 (4; 11) years.
b values express intragroup differences between coronary event time and last visit (after event).
PI: protease inhibitors; NNRTI: nonnucleoside analog reverse-transcriptase inhibitors.